Early de novo malignancies after kidney transplantation

Veroux, Massimiliano; Puliatti, Carmelo; Fiamingo, Pietro; Cappello, D.; Macarone, M.; Puliatti, D; Vizcarra, Darwin; Gagliano, M.

doi:10.1016/j.transproceed.2004.03.021

Cited by 34 publications

(27 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18 Several studies have reported an increased incidence of malignancy (6%-11%) among organ transplant recipients. [1][2][3][4][5][6] The incidence of malignancy has been reported to correlate with the time and intensity of immunosuppression. 4,19 However, controversy exists as to the correlations between malignancy incidence and geographic factors, malignancy type, donor source, and the pattern of rejection episodes.…”

Section: Treatment and Prognosesmentioning

confidence: 99%

“…The current study findings are also consistent with those of previous reports showing that skin cancer and Kaposi's sarcoma are the 2 most common carcinomas in renal allograft recipients. [2][3][4][5] Recent studies have shown a progressive increase in the incidence of thyroid carcinoma in the general population.…”

Section: Treatment and Prognosesmentioning

confidence: 99%

“…27 The present study observed a greater incidence of stomach carcinoma (0.7%) and thyroid carcinoma (0.7%) compared with other studies. [2][3][4][5] Such data may be due to geographic or ethnic factors, since the incidences of stomach and thyroid carcinoma have recently progressively increased in Korea. According to the KCCR data, the age-adjusted annual incidence of thyroid carcinoma has progressively increased from 5.6 new cases per million in 1995-1999 to 19.2 in 2004 in the Korean general popula- …”

Section: 1023-26mentioning

confidence: 99%

“…[1][2][3][4][5] The chronic use of immunosuppressive drugs to prevent allograft rejection increases the long-term risk for carcinoma. [1][2][3][4][5][6] The overall incidence of malignancy ranges from 6% to 11% among renal allograft recipients.…”

mentioning

confidence: 99%

“…[3][4][5] However, controversy exists regarding the incidence and prognosis of such cases. 6,7 The incidence of papillary thyroid carcinoma (PTC) in the general population is increasing worldwide.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Incidence and Clinical Behavior of Papillary Thyroid Carcinoma in Renal Allograft Recipients: A Single Center Experience

Lee

Jeong

Lee

et al. 2008

Transplantation Proceedings

View full text Add to dashboard Cite

Section: Treatment and Prognosesmentioning

confidence: 99%

Section: Treatment and Prognosesmentioning

confidence: 99%

Section: 1023-26mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Incidence and Clinical Behavior of Papillary Thyroid Carcinoma in Renal Allograft Recipients: A Single Center Experience

Lee

Jeong

Lee

et al. 2008

Transplantation Proceedings

View full text Add to dashboard Cite

Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer

Basté

2022

Cancer Medicine

View full text Add to dashboard Cite

In this article, we focus on a variety of immunosuppression scenarios and whether multikinase inhibitors, as systemic therapy for advanced thyroid carcinoma (TC), could be useful for the treatment of immunocompromised patients with TC.Lenvatinib and sorafenib, among other MKIs, have become the standard of care for advanced TC based on their efficacy data and despite their adverse effects.Currently, published data on MKIs in immunosuppressed patients are scarce.Secondary malignancies can arise in immunosuppressed patients who have undergone solid organ transplantation, human immunodeficiency virus-infected patients, and hematopoietic stem cell transplant recipients. This review will explore different immunosuppression settings, the risk of secondary malignancies in immunosuppressed patients, and the special characteristics of this population. Some considerations regarding anticancer treatment in immunosuppressed patients with advanced malignancies are reviewed. K E Y W O R D Simmunosuppressed patients, multikinase inhibitors, systemic treatment, thyroid carcinoma How to cite this article: Basté Rotllan N. Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer.

show abstract

Risk acceptance in composite-tissue allotransplantation reconstructive procedures

et al. 2006

View full text Add to dashboard Cite

Composite-tissue allotransplantation (CTA) is a new therapeutic modality to reconstruct major tissue defects of the face, larynx, and extremities. Unlike most life-saving organ-transplantation procedures, CTA is considered to improve quality of life. Therefore, the question arises, do the risks posed by the immunosuppression drugs that patients must take to prevent rejection justify the benefits of these procedures? The purpose of this study was to assess the relative risk that individuals are willing to accept in order to receive the benefits of CTA procedures. We used a psychometrically reliable and valid instrument to question two primary populations of individuals: those who live with the risks of immunosuppression, and healthy individuals. The level of risk acceptance for the seven transplant procedures tested (foot, single hand, double hand, larynx, kidney, hemiface, and full face) showed significant differences in research participants' risk acceptance for the different transplant procedures, but no significant differences between groups. Based on these findings, we conclude that certain CTA procedures convey benefits to recipients that are perceived by subjects, including individuals who live with the risks of immunosuppression, to warrant the risks of these procedures.

show abstract

Early de novo malignancies after kidney transplantation

Cited by 34 publications

References 11 publications

Incidence and Clinical Behavior of Papillary Thyroid Carcinoma in Renal Allograft Recipients: A Single Center Experience

Incidence and Clinical Behavior of Papillary Thyroid Carcinoma in Renal Allograft Recipients: A Single Center Experience

Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer

Risk acceptance in composite-tissue allotransplantation reconstructive procedures

Contact Info

Product

Resources

About